Insider · SEC Form 4 filer
Jean Bienaime
Past buys: 3 of 6 beat
Companies
Where they file as an insider
Keros Therapeutics (KROS) Director Latest filing Aug 17, 2026
Ascendis Pharma A/S (ASND) Director Latest filing Aug 14, 2026
Incyte (INCY) Director Latest filing Jun 8, 2026
Immunome (IMNM) Director Latest filing Jun 5, 2026
Biomarin Pharmaceutical (BMRN) Director Latest filing May 20, 2024
Track record
Did their buys beat the typical stock?
Open-market buys24
Quarters checked 6 months later6
Beat the typical stock 3 of 6
Quarters too new to check5
3 of 6 checked quarters beat the typical stock. A past record is data, not a forecast.
Ascendis Pharma A/S (ASND) Bought Aug 14, 2026 · $493K · 2,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Keros Therapeutics (KROS) Bought Jul 15–Aug 17, 2026 · $20.9K · 2,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Ascendis Pharma A/S (ASND) Bought May 26–29, 2026 · $207K · 900 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Immunome (IMNM) Bought May 15–Jun 5, 2026 · $308K · 15,500 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Keros Therapeutics (KROS) Bought Apr 15–Jun 15, 2026 · $32.5K · 3,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Immunome (IMNM) Bought Mar 10–11, 2026 · $43.7K · 2,000 shares Behind typical Mar 31, 2026 $21.87 → Sep 30, 2026 $21.51 · −1.6% (typical stock +1.7%)
Keros Therapeutics (KROS) Bought Mar 9, 2026 · $22.4K · 2,000 shares Beat typical Mar 31, 2026 $11.04 → Sep 30, 2026 $11.40 · +3.3% (typical stock +1.7%)
Immunome (IMNM) Bought Jun 3, 2025 · $46.9K · 5,000 shares Beat typical Jun 30, 2025 $9.30 → Dec 31, 2025 $21.48 · +131.0% (typical stock +2.1%)
Immunome (IMNM) Bought Mar 24–25, 2025 · $118K · 14,800 shares Beat typical Mar 31, 2025 $6.73 → Sep 30, 2025 $11.71 · +74.0% (typical stock +7.3%)
Immunome (IMNM) Bought Aug 16, 2024 · $97.6K · 7,000 shares Behind typical Sep 30, 2024 $14.62 → Mar 31, 2025 $6.73 · −54.0% (typical stock −7.5%)
Immunome (IMNM) Bought May 21, 2024 · $27.1K · 2,000 shares Behind typical Jun 30, 2024 $12.10 → Dec 31, 2024 $10.62 · −12.2% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.